Van­da's gas­tric drug flops in late-stage test, crash­ing the biotech's stock

You may re­mem­ber Van­da Phar­ma­ceu­ti­cals from its brief feud with the FDA over a par­tial clin­i­cal hold on gas­tric drug tradip­i­tant — a fight it would lose in court a cou­ple years ago. Now, that same drug is in hot wa­ter af­ter fail­ing a piv­otal test.

Tradip­i­tant, an in-li­censed drug from Eli Lil­ly be­ing test­ed in gas­tro­pare­sis, flopped a Phase III study look­ing to re­duce nau­sea symp­toms against place­bo, the biotech said Fri­day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN